EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Harmane inhibits hepatic cytochrome P450 enzymes in rats

E Klásková, O Zendulka, O Peš, S M Eyrilmez, D Bednář, J Juřica

Frontiers in Pharmacology · 17.08.2026 · 17

DOI: 10.3389/fphar.2026.1863858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.08.2026. Verfasst von E Klásková und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lékařská Fakulta, Masarykova Univerzita.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Harmane (HAR) is a beta‐carboline alkaloid found in plants, heat‐processed foods, and tobacco. It is an active component of widely used antidepressant and anxiolytic herbs. In this study, we investigate the effects of HAR on rat CYP enzymes both in vivo and in vitro and examine the interactions between HAR and human CYP enzymes through in silico methods.

Methods

The impact of subchronic premedication with HAR at doses of 25, 40, and 64 mg/kg on CYP enzyme activity was evaluated in rats using CYP‐specific probe substrates of CYP1A2, CYP2A, CYP2B, CYP2C6, CYP2C11, CYP2D1/2, and CYP3A1/2. In vitro inhibitory assays of HAR were conducted. Finally, HAR was docked in silico into human CYP enzyme active sites. Results and Discussion HAR premedication significantly decreased the protein content and metabolic activity of rat CYP2B1, CYP2C11, CYP2D1/2, and CYP3A1/2. In vitro , HAR showed moderate inhibition of CYP2A1 and CYP3A1/2 (IC50 values of 14.0 and 1.2 µM, respectively) and no inhibition of the other enzymes tested. In silico docking studies with human CYP enzymes confirmed that HAR has the potential for CYP‐mediated drug–drug inhibitory interactions. In summary, HAR significantly inhibited the activities of several drug‐metabolizing CYP enzymes in the preclinical model. These findings suggest the need for further research into HAR’s pharmacokinetic interactions.

Schlagwörter

Stichwörter der Autor:innen

cytochrome P450drug interactionharmaneinhibitionratß-carboline

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia.
  • Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czechia.
  • Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czechia.
  • International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
  • Hospital Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czechia.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University, Brno, Czechia.

Förderung

  • Lékařská Fakulta, Masarykova Univerzita

Zitieren

APA

Klásková, E., Zendulka, O., Peš, O., Eyrilmez, S. M., Bednář, D., & Juřica, J. (2026). Harmane inhibits hepatic cytochrome P450 enzymes in rats. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1863858

Vancouver

Klásková E, Zendulka O, Peš O, Eyrilmez SM, Bednář D, Juřica J. Harmane inhibits hepatic cytochrome P450 enzymes in rats. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1863858

BibTeX
@article{Klskov2026,
  author = {Klásková, E and Zendulka, O and Peš, O and Eyrilmez, S M and Bednář, D and Juřica, J},
  title = {Harmane inhibits hepatic cytochrome P450 enzymes in rats},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1863858}
}
Kostenlos starten →